Results 81 to 90 of about 19,002 (159)

Three-month outcome of intravitreal ziv-aflibercept in eyes with diabetic macular oedema [PDF]

, 2017
Purpose We report the 3-month efficacy of monthly intravitreal ziv-aflibercept in patients with diabetic macular oedema (DME). Methods Prospectively, consecutive patients with DME underwent intravitreal injection of 0.05 ml of compounded ziv-aflibercept (
Mansour, Ahmad Mohammed Farid Mahmoud, Chhablani, Jay Kumar, Dedhia, Chintan Jethalal   +2 more
core   +1 more source

Short-term Anatomical and Functional Outcomes of Intravitreal Ziv-aflibercept for Macular Edema Secondary to Central Retinal Vein Occlusion: A Prospective Pilot Interventional Case Series

Zagazig University Medical Journal
Background: Central retinal vein occlusion (CRVO) may cause substantial central visual impairment, particularly when macular edema develops. This study evaluated the 24-week visual, anatomical, and safety outcomes of intravitreal ziv-aflibercept in eyes ...
Ahmed Saber, Sherif Dabour, Ahmad Khalil, Ahmed Alyan   +3 more
doaj   +1 more source

Incidence and management of ZIv-aflibercept related toxicities in colorectal cancer

World Journal of Clinical Oncology, 2014
Ziv-afilbercept (Zaltrap, Ziv) is a humanized fusion protein constructed by joining the vascular endothelial growth factor (VEGF) binding portions of human VEGF receptors 1 and 2 to the Fc portion of human immunoglobulin IgG1. Recently, a randomized, open-label, phase III study compared 5-fluorouracil, leucovorin, irinotecan (FOLFIRI)/Ziv with FOLFIRI ...
Muhammad Wasif, Saif, Valerie, Relias, Kostas, Syrigos, Krishna S, Gunturu   +3 more
openaire   +2 more sources

Baseline characteristics of 20 eyes on treatment with intravitreal ziv-aflibercept.

, 2019
Baseline characteristics of 20 eyes on treatment with intravitreal ziv-aflibercept.
Stephen Akafo (348360), Kwesi N. Amissah-Arthur (7541804), Imoro Zeba Braimah (7541801), Winfried M. Amoaku (7541810), Ernest Kenu (664172), Kwaku Oppong Kwarteng (7541807)   +5 more
core   +1 more source

Efficacy of intravitreal injection of Ziv-aflibercept before vitrectomy for proliferative diabetic retinopathy

Delta Journal of Ophthalmology
Purpose The aim of this study was to evaluate the efficacy of intravitreal injection of Ziv-aflibercept before small-gauge pars plana vitrectomy compared to pars plana vitrectomy alone in eyes with advanced diabetic eye disease. Patients and methods
Amin E. Nawar, Ahmed R. Alagorie
doaj   +1 more source

The short- and long-range RNA-RNA Interactome of SARS-CoV-2. Ziv et al.

Supplemental files accompanying Ziv et al.'s paper "The short- and long-range RNA-RNA Interactome of SARS-CoV ...
Ziv, O
core   +1 more source

Error-resilient scheme for wavelet video codec using automatic ROI detection and Wyner-Ziv coding over packet erasure channel [PDF]

, 2010
This is the author's accepted manuscript. The final published article is available from the link below. Copyright @ 2010 IEEE. Personal use of this material is permitted.
Loo, K.K., Lifang Feng, Feng, L, Cosmas, J., Feng, L., Loo, KK, Zhuo Xue, Kok Keong Loo, Tun, M, Myo Tun, Xue, Z, Pik-Yee Yip, Tun, M., Yip, P-Y, Cosmas, J, Yip, P.Y., John Cosmas, Xue, Z., Yip, P., Loo, J.   +19 more
core   +1 more source

Ziv-aflibercept in metastatic colorectal cancer

Biologics: Targets & Therapy, 2013
Anuj Patel, Weijing Sun Division of Hematology-Oncology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA Abstract: The combination of cytotoxic chemotherapy and antiangiogenic agents has become
Patel A, Sun W
doaj  

Safety of Intravitreal ziv-aflibercept

, 2017
Purpose: 1. To evaluate the viability of ARPE-19 human retinal pigment epithelial cells after exposure to ziv-aflibercept 12.5 and 25 mg/mL; 2. To evaluate the safety of intravitreal ziv-aflibercept in an experimental rabbit model; 3.
Dias, João Rafael de Oliveira [UNIFESP]
core  

North American (NA) subgroup results from VELOUR: Ziv-aflibercept versus placebo (pbo) plus FOLFIRI in mCRC that is resistant to or has progressed after an oxaliplatin-containing regimen.

, 2013
465 Background: Ziv-aflibercept (trade name ZALTRAP; known outside the US as aflibercept) is a new multiple angiogenic inhibitor that prevents VEGF-A, VEGF-B and PLGF from binding their receptors.
Michael L. Andria, Emmanuelle Boelle, Pankaj Bhargava, Jeffrey J. Kirshner, Michael J. Guarino, Edith P. Mitchell, Carmen Joseph Allegra   +6 more
core   +1 more source